Eli Lilly And Co LLY will be reporting its first-quarter earnings on Thursday. Wall Street expects $3.05 in EPS and $12.67 billion in revenues as the company reports before market hours.The stock is up 14.35% over the past year, 14.79% YTD.Let’s examine the charts for Eli Lilly stock and how it currently compares to Wall Street estimates.Read Also: $1000 Invested In This Stock 20 Years Ago Would Be Worth This Much TodayLLY Stock Chart Strongly Bullish Ahead Of Q1 EarningsChart created using Benzinga ProEli ...

Growth stocks often don't come cheap, especially when their prospects look great, as is the case with Eli Lilly (LLY 1.09%). It is the most valuable healthcare company in the world, with a market cap of around $800 billion. And yet it may still not be too late to invest in it.The company's dominance in the GLP-1 drug market makes it a promising long-term investment to hang on to. Last year, its sales rose by 32%, but there could be even more growth on the horizon.Eli Lilly is going after compounding pharmac ...

I publish my best ideas and top coverage on the Growth Stock Forum . If you're interested in finding great growth stocks, with a focus on biotech, consider signing up. We focus on attractive risk/reward situations and track each of our portfolio and watchlist stocks closely. To receive e-mail notifications for my public articles and blogs, please click the follow button . And to go deeper, sign up to Growth Stock Forum.The last couple of quarters have been very favorable for Eli Lilly and Company (NYSE: LLY ...

Eli Lilly and Company (LLY) will report its first-quarter earnings on May 1, before market open. The Zacks Consensus Estimate for sales and earnings is pegged at $12.62 billion and $3.52 per share, respectively. Earnings estimates for 2025 have declined from $23.53 to $22.43 per share over the past 30 days. (Find the latest earnings estimates and surprises on Zacks Earnings Calendar.)Image Source: Zacks Investment ResearchLLY’s Earnings Surprise HistoryThe healthcare bellwether’s performance has been mixed, ...

Eli Lilly And Co (NYSE:LLY) stock is 1.6% lower to trade at $870.31 at last check, after a rare double downgrade from HSBC to "reduce" from "buy," and a price-target cut to $700 from $1,150. The analyst in coverage cited strong competition and valuation concerns. Coming into today, the majority of analysts were bullish toward the equity. In fact, 22 of 25 firms in coverage sport a "buy" or better rating, while the 12-month consensus target price of $998.05 is a 14.3% premium to current levels.Despite today' ...

Eli Lilly and Company (LLY) will report its first-quarter earnings on May 1, before market open. The Zacks Consensus Estimate for sales and earnings is pegged at $12.62 billion and $3.52 per share, respectively. Earnings estimates for 2025 have declined from $23.53 to $22.43 per share over the past 30 days. (Find the latest earnings estimates and surprises on Zacks Earnings Calendar.)Image Source: Zacks Investment ResearchLLY’s Earnings Surprise HistoryThe healthcare bellwether’s performance has been mixed, ...

Originally a Biologist, M.Sc in Biomedicine, PhD in Bioengineering, with +20 years experience in the research and development of novel Cell & Gene Therapies (CGT) tackling several clinical needs. As an investor, I have been utilising my background in life sciences to assess the potential of novel treatments, including those using CGT, as well as, their capacity to drive shareholders' returns. Thus, as SA analyst, I will be focusing on analysing biotechnology, pharmaceutical, Medtech and healthcare stocks, p ...

文章核心观点 - 尽管有管道药物的利好消息 但分析师下调礼来公司股价目标 不过仍认为该股票有价值 [1] 分析师对礼来公司的操作 - 周四上午 蒙特利尔银行资本市场的Evan David Seigerman将礼来公司的股价目标下调110美元 新的公允价值评估为每股900美元 同时维持对该股的跑赢大盘（即买入）评级 [2] 分析师对礼来公司的看法 - 分析师看好公司目前最热门的产品（减肥药物Zepbound） 但对更广泛的宏观经济环境表示担忧 认为经济压力正在影响整个医疗保健行业 礼来公司作为美国制药业的标杆易受影响 [3] - 分析师对公司在Zepbound上的发展势头印象深刻 研究表明该药物明显领先于生产Wegovy的诺和诺德 后者是美国食品药品监督管理局唯一批准的专门用于减肥的GLP - 1疗法 [4] 行业情况及对礼来公司的影响 - 当前全球宏观经济动荡 只要当前贸易战在一定程度上持续 可能仍会不稳定 但制药公司比大多数行业更能抵御这种情况 因为许多药物并非奢侈品或可选项 礼来公司仍是值得持有的优质股票 [5]

文章核心观点 - 礼来公司起诉四家远程医疗公司销售其减肥药物Zepbound和糖尿病治疗药物Mounjaro的复方版本，打击仿制药行业 [1] 礼来公司诉讼情况 - 周三提起诉讼，指控Mochi Health、Fella Health、Willow Health和Henry Meds四家网站欺骗消费者，推销未经测试和批准的药物，使消费者远离礼来药品 [2] - 指控这些公司声称提供个性化选择，实际批量销售礼来药物的略有不同版本以规避FDA规则，还销售未经研究的剂型如口服片剂和滴剂 [3] - 指控Mochi Health的首席执行官并非执业医师，该公司及其未获许可的所有者对医生的处方决定施加不当影响和控制，存在“非法的公司行医行为” [8] - 对Fella Health提出类似指控，称其做出影响患者护理的全面公司决策，如大规模更换患者的替尔泊肽配方 [8] - 礼来公司寻求阻止这些网站营销或销售替尔泊肽，但案件可能需要数月甚至更长时间才能通过法院审理 [8] 复方药物市场背景 - 2022年末礼来糖尿病药物Mounjaro供应短缺，诺和诺德减肥药物Wegovy也供应短缺，促使药房和外包机构进行复方药物生产，该业务在网上蓬勃发展 [4] - 上个月FDA宣布药物短缺结束后，Mounjaro和Zepbound的活性成分替尔泊肽的大规模复方生产本应停止，但一些药房仍在继续生产略有不同的版本以避开FDA监管 [5][6] 涉事公司回应情况 - Mochi Health、Fella Health、Willow Health和Henry Meds未立即回应CNBC的置评请求 [4] - Mochi Health首席执行官Myra Ahmad曾表示计划继续销售替尔泊肽复方版本，认为提供个性化治疗可避免法律麻烦，且不担心医生面临法律诉讼 [7][8]

Since the last time I wrote about weight loss-leader Eli Lilly (NYSE: LLY ) in November last year, its price is up by 11%. Increase was indicated by its market multiples at that time. However, I had gone with a Hold rating on theManika is a macroeconomist with over 20 years of experience in industries including investment management, stock broking, investment banking. She also runs the profile Long Term Tips [LTT], which focuses on the generational opportunity in the green economy. Her investing group, Gree ...